Moulder Named CEO Of Abraxis BioScience
April 30, 2009 (FinancialWire) — Abraxis BioScience, Inc. (NASDAQ: ABII) has appointed Leon O. Moulder, Jr. as vice chairman, president and chief executive officer. Patrick Soon-Shiong, M.D., who held the positions of chairman and CEO of Abraxis BioScience since founding the company, will assume the role of executive chairman and CEO of the firm’s new Abraxis Health unit, which is slated to be spun off from ABII.
Moulder most recently served as vice chairman of Eisai Corp. of North America following Eisai’s acquisition of MGI Pharma, where he served as president and CEO since 2003. Moulder joined MGI Pharma in 1999 as EVP and was promoted to president and chief operating officer in 2002.
Before MGI Pharma, Moulder was a member of the founding management team and VP for business development and commercial affairs of Eligx, a venture-stage biomedical company. Before that he served for 16 years in a number of commercial roles for Hoechst Marion Roussel and its predecessor companies.
The company said that Abraxis Health will focus on biomarkers and personalized medicine. Soon-Shiong will assume the role of CEO, while Edward Geehr will be the president and COO. Bruce Wendel will be Abraxis Health’s vice chairman and EVP for global business development.
Los Angeles-based Abraxis BioScience is a biotechnology company focused on the discovery, development and delivery of therapeutics and core technologies for the treatment of cancer and other critical illnesses.
The company’s portfolio includes a protein-bound nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting technology known as the nab platform. The first FDA approved product to use this nab platform, Abraxane, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
